Inclusion Criteria:

- Non-child bearing potential or able to follow birth control requirements

- Eastern Cooperative Oncology Group (ECOG) 1

- Life expectancy 12 weeks

- Laboratory criteria as:

- Neutrophil count 1,500/mm3

- Platelet count 7.5 x 104 /mm3

- Hemoglobin 9.0 g/dL

- Lymphocyte count 500/mm3

- Serum creatinine < 1.5 x institutional Upper Limit of Normal (ULN) or an
estimated glomerular filtration rate (eGFR) of > 50 ml/min as calculated by the
Modification of Diet in Renal Disease (MDRD) equation

- Total bilirubin < 1.5 x ULN (except for subjects with documented Gilbert's
syndrome)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN

- Dose escalation subjects: Epidermal Growth Factor Receptor (EGFR) activating mutation
by local testing: exon 18 G719X, exon 19 deletion, exon 21 L861Q, exon 21 L858R or
exon 20 insertion; and received prior treatment with EGFR Tyrosine Kinase Inhibitor
(TKI)

- Response expansion/RP2D expansion/ FE Cohort subjects: disease progression on or was
intolerant to prior EGFR TKI; activating mutation as above AND T790M mutation; tumor
sample subsequent to EGFR TKI is available for central testing; at least one
measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Exclusion Criteria:

- Any ongoing toxicity Grade 2 attributable to prior Non-Small-Cell Lung Cancer
(NSCLC) treatment

- Prior EGFR inhibitor within 6 days; received prior treatment with any other agent
with antitumor activity chemotherapy, radiotherapy, or immunotherapy within 14 days;
any investigational therapy within 28 days or 5 half-lives, whichever is shorter;
blood transfusion or hemopoietic factor within 14 days; major surgery within 14 days;
any strong CYP3A4 inhibitors within 7 days

- Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) or
Human Immunodeficiency Virus (HIV)

- Symptomatic Central Nervous System (CNS) metastasis

- Active infection requiring systemic therapy within 14 days

- Severe or uncontrolled systemic diseases including uncontrolled hypertension

- History of or active interstitial lung disease

- Screening QTcF >450 msec or current medication known to prolong QT

- Grade 2 cardiac arrhythmia or uncontrolled atrial fib of any grade; Class 3 or 4
New York Heart Association congestive heart failure; history of severe/unstable
angina, myocardial infarction or cerebrovascular accident within 6 months

- History of gastrointestinal ulcer or bleeding within 3 months; any digestive tract
dysfunction

- Concurrent corneal disorder or ophthalmologic condition making subject unsuitable

- RP2D cohort subjects: contraindications to midazolam, any other midazolam within 7
days, or any medications or supplements known to be strong CYP3A inhibitors within 7
days or inducers within 12 days

- Any other malignancy requiring treatment

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both